Erratum: Chemotherapy in metastatic NSCLC - new regimens (pemetrexed, nab-paclitaxel) [Front Oncol, 4, 177, (2014)] doi:10.3389/fonc.2014.00177;Chemotherapy in metastatic NSCLC - new regimens (pemetrexed, nab-paclitaxel)

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Blais, Normand ^a   Hirsh, Vera ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Clinical trials; Histology; Metastatic; Nab paclitaxel; Non small cell lung carcinoma; Pemetrexed; Solvent based paclitaxel

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CREMOPHOR; CYANOCOBALAMIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOLIC ACID; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; POLYSORBATE 80; STEROID;

ADENOCARCINOMA; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SHORT SURVEY; THROMBOCYTOPENIA;

EID: 84904598189     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00300     Document Type: Erratum

References (50)

1. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 11(6):645-53.
2. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol (2009) 27(36):6251-66. doi: 10.1200/JCO.2009.23.5622
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med (2002) 346(2):92-8. doi:10.1056/NEJMoa011954
4. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 19(13):3210-8.
5. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol (2008) 26(21):3543-51. doi:10.1200/JCO.2007.15.0375
6. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol (2002) 20(21):4285-91. doi:10.1200/JCO.2002.02.068
7. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 21(16):3016-24. doi:10.1200/JCO.2003.12.046
8. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol (2000) 18(3):623-31.
9. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol (2000) 18(19):3390-9.
10. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer lung cancer group - EORTC 08975. J Clin Oncol (2003) 21(21):3909-17. doi:10.1200/JCO.2003.03.195
11. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 23(4):857-65. doi:10.1200/JCO.2005.08.043
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129-39. doi:10.1056/NEJMoa040938
13. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 101(36):13306-11. doi:10.1073/pnas.0405220101
14. Paik PK, Hasanovic A, Wang L, Rekhtman N, Ladanyi M, Kris MG. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol (2012) 30(15 Suppl):Abstr 7505
15. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med (2008) 359(13):1367-80. doi:10.1056/NEJMra0802714
16. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol (2011) 29(18 Suppl):Abstr CRA-7506
17. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol (2008) 3(1):13-7. doi:10.1097/JTO.0b013e31815e8b60
18. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res (2008) 14(20):6618-24. doi:10.1158/1078-0432.CCR-08-1018
19. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature (2007) 448(7153):561-6. doi:10.1038/nature05945
20. Saliba W, Corrales-Rodriquez L, Albadine R, Soulieres D, Weng X, Gorska I, et al. Retrospective analysis of the prevalence of NSCLC driver mutations in unselected samples. J Thorac Oncol (2013) 8(Suppl 2):S672; Abstr P1.18-021, [poster].
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489(7417):519-25. doi:10.1038/nature11404
22. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 18(4):1167-76. doi:10.1158/1078-0432.CCR-11-2109
23. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet (2009) 373(9674):1525-31. doi:10.1016/S0140-6736(09)60569-9
24. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, et al. Global lung oncology branch trial 3 (GLOB3): final results of a randomized multinational phase III study alternating oral and iv vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small cell lung cancer. Ann Oncol (2009) 20(7):1249-56. doi:10.1093/annonc/mdn774
25. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol (2010) 28(11):1835-42. doi:10.1200/JCO.2009.26.1321
26. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol (2010) 28(6):911-7. doi:10.1200/JCO.2009.21.9618
27. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 44(5):372-80. doi:10.1007/s002800050992
28. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 22(9):1589-97. doi:10.1200/JCO.2004.08.163
29. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol (2003) 66(3):431-8. doi:10.1016/S0006-2952(03)00287-9
30. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer (2006) 107(7):1589-96. doi:10.1002/cncr.22208
31. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol (2003) 21(8):1556-61. doi:10.1200/JCO.2003.06.122
32. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 6(1):64-70. doi:10.1097/JTO.0b013e3181f7c6d4
33. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol (2013) 31(23):2895-902. doi:10.1200/JCO.2012.47.1102
34. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol (2013) 31(24):3004-11. doi:10.1200/JCO.2012.42.3749
35. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet (2009) 374(9699):1432-40. doi:10.1016/S0140-6736(09)61497-5
36. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 27(19):3217-24. doi:10.1200/JCO.2008.20.9114
37. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. Point break: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol (2013) 31(34):4349-57. doi:10.1200/JCO.2012.47.9626
38. Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, et al. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer (2014) 120(9):1379-86. doi:10.1002/cncr.28591
39. Abraxane for Injectable Suspension (Albumin-Bound), 100 mg/20 ml (Vial), Single-Use for Intravenous Infusion, Sterile, Lyophilized Solution. Celgene Corporation (2005).
40. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles implications for cancer chemotherapy. Clin Pharmacokinet (2003) 42(7):665-85. doi:10.2165/00003088-200342070-00005
41. Taxol, a Paclitaxel Injection [Semi-Synthetic] Solution, for Intravenous Use, Multi-Dose Vial (MDV), 6 mg/ml. Princeton, NJ: Bristol-Myers Squibb Co (2011).
42. Taxotere, a Docetaxel for Injection, in a Concentrated Solution [20 mg/ml, 80 mg/4 ml, 160 mg/8 ml], One Vial, Single-Use, in Docetaxel Anhydrous, Sterile, Non-Pyrogenic, Non-Aqueous Solution, Intravenously Administered. Bridgewater, NJ: Sanofi-Aventis (2010).
43. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol (1990) 8(7):1263-8.
44. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 37(13):1590-8. doi:10.1016/S0959-8049(01)00171-X
45. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 12(4):1317-24. doi:10.1158/1078-0432.CCR-05-1634
46. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: final results of a phase III trial. J Clin Oncol (2012) 30(17):2055-62. doi:10.1200/JCO.2011.39.5848
47. Socinski MA, Langer CJ, Okamoto I, Hirsh V, Dakhil SR, Page RD, et al. Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small cell lung cancer. Ann Oncol (2013) 24(2):314-21. doi:10.1093/annonc/mdt235
48. Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol (2013) 24(9):2390-6. doi:10.1093/annonc/mdt235
49. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 24(10):1633-42. doi:10.1200/JCO.2005.04.0543
50. Hirsh V, Okamoto I, Hon JK, Page RD, Orsini J, Sakai H, et al. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2014) 9(1):83-90. doi:10.1097/JTO.0000000000000011